What is the story about?
What's Happening?
Plus Therapeutics has secured a national agreement with UnitedHealthcare to provide its CNSide Cerebrospinal Fluid Tumor Cell Enumeration test, effective September 15, 2025. This agreement potentially opens access to over 51 million covered lives. The CNSide test, used for diagnosing and monitoring leptomeningeal metastases, has been performed over 11,000 times since 2020, showing high sensitivity and specificity. Following the announcement, Plus Therapeutics' stock surged by approximately 60% in premarket trading. The company also received additional funding from CPRIT, bolstering its financial position.
Why It's Important?
The agreement with UnitedHealthcare represents a significant milestone for Plus Therapeutics, enhancing the accessibility of its CNS cancer test. This coverage could lead to increased adoption of the test, providing clinicians with a valuable tool for managing advanced cancer complications. The stock surge reflects investor confidence in the company's growth prospects and the potential for increased revenue. The deal underscores the importance of payer support in expanding access to innovative diagnostic tools in the healthcare industry.
What's Next?
Plus Therapeutics will likely focus on expanding its market presence and securing additional payer agreements to further increase test accessibility. The company may also explore opportunities to integrate the CNSide test with its other cancer treatment programs. Monitoring the test's adoption and impact on patient outcomes will be crucial in assessing its long-term success.
AI Generated Content
Do you find this article useful?
